Have you or someone you know been through Blincyto immunotherapy after chemotherapy?
Yes, many people have received Blincyto after chemotherapy. Blincyto is specifically approved for B-cell acute lymphoblastic leukemia (ALL) that has either relapsed after treatment or isn't responding to chemotherapy. It's used as a Show Full Answer
Have you or someone you know been through Blincyto immunotherapy after chemotherapy?
Yes, many people have received Blincyto after chemotherapy. Blincyto is specifically approved for B-cell acute lymphoblastic leukemia (ALL) that has either relapsed after treatment or isn't responding to chemotherapy. It's used as a second-line treatment when initial therapies haven't eliminated the cancer cells or when they've returned.
Studies show promising results. In one study of children and young adults up to age 30 with relapsed ALL, those who received Blincyto had a 79% overall survival rate compared to 59% for standard chemotherapy. They also experienced fewer severe side effects like fever, infection, and sepsis.
The treatment typically starts in the hospital for monitoring, then continues at home or at an outpatient clinic with a portable IV pump. Treatment usually lasts four weeks, with a two-week break before a second cycle if needed.
Common side effects include fever, headache, and infection. Some people experience neurological symptoms like confusion, difficulty speaking, or seizures. A rare but serious side effect is cytokine release syndrome, which causes an inflammatory reaction.
March 16
Join
Your Privacy Choices
